Real-world study explores new drug for breast cancer
NCT ID NCT05851677
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is looking at how well a drug called Disitamab vedotin (RC48-ADC) works for breast cancer patients in real-world settings, outside of strict clinical trials. Researchers will track 45 patients to see how long they live without their cancer getting worse and what side effects occur. The goal is to understand the drug's true effectiveness and safety when used in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Disitamab vedotin (RC48-ADC)
What this could lead to
If successful, this could provide real-world evidence that Disitamab vedotin is a safe and effective treatment option for breast cancer patients.
What could go wrong
This is a small, observational study with only 45 participants, so results may not apply to all breast cancer patients. It is not a randomized controlled trial, so effectiveness is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••